Vir Biotechnology Inc V.VIR

Primary Symbol: VIR

Healthcare Biotechnology

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.

NDAQ:VIR - Post by User

Vir Biotechnology Inc > Experion Wellness = 130 followers on twitter

<< Previous

Bullboard Posts

Next >>

Comment by igotit01on Nov 09, 2019 11:41am

74 Views

Post# 30331332

RE:RE:RE:RE:RE:Experion Wellness = 130 followers on twitter

What does oil sector have to do with weed company here ?

dont expect oil sector to raise.. there is always a law suite and case filed against trans can pipeline which will never complete....

didn't u hear the new of husky firing their employees in cal as no hope in Canada oil sector

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading